The drug Sacituzumab govitecan-hziy is recommended by healthcare professionals to treat metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. This drug is sold under the brand name Trodelvy. Trodelvy single-dose vials are supplied in 180 mg and 200 mg to administer intravenously. The common Trodelvy side-effects are neutropenia, nausea, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite, rash and abdominal pain. The medicine Trodelvy was permanently discontinued for adverse reactions in 2% of patients. Adverse reactions leading to discontinuation were anaphylaxis, anorexia/fatigue, headache (each

Note : If you make a call this number [ 09310090915 ] Please mention that you have seen this ad in Adsfeast a classifieds website.....